ALACHUA, Fla.--(BUSINESS WIRE)--RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, reported operating results for the first quarter of 2011 as follows: “We are pleased with our first quarter results, which exceeded our expectations and were driven primarily by continued growth in our surgical specialties and direct sports medicine businesses,” said Brian K. Hutchison, chairman and CEO of RTI. “Revenues in the spine business were up slightly on a sequential quarter basis; however, it is still too early to determine if market pressures are abating. The decrease in reported dental revenues is the result of the change in terms of our distributor agreement, which was announced in the third quarter of 2010. If the new terms with our distributor had been effective in the first quarter of 2010, dental revenues would have increased by 4 percent.”
